Evommune (EVMN) Profit After Tax (2024 - 2026)

Evommune (EVMN) has reported Profit After Tax for 3 consecutive years, with -$21.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 48.89% year-over-year to -$21.7 million; the TTM figure through Mar 2026 stood at -$77.0 million (changed N/A YoY), while the FY2025 annual figure was -$68.9 million, down 3.09% from the prior year.
• Profit After Tax advanced to -$21.7 million in Q1 2026 per EVMN's latest filing, from -$28.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$12.5 million in Q3 2025 and bottomed at -$28.3 million in Q4 2025.
• Historically, Profit After Tax has averaged -$18.9 million across 3 years, with a median of -$18.3 million in 2024.
• Annual changes were most pronounced in 2025 — Profit After Tax gained 21.62% — and 2026, when it plunged 48.89%.
• Evommune's Profit After Tax stood at -$20.7 million in 2024, then slumped by 36.41% to -$28.3 million in 2025, then grew by 23.34% to -$21.7 million in 2026.
• Business Quant data shows EVMN's Profit After Tax at -$21.7 million in Q1 2026, -$28.3 million in Q4 2025, and -$12.5 million in Q3 2025.